Funding

AMR Action Fund

Capital Type

Venture Capital, Corporate Venture Capital

Investment Size

~$20M–$100M+

Geographic Scope

Global

Return Model

Dilutive

Stage Focus

Clinical, Commercial

Modality Focus

Late-stage antibiotics, Antifungals

Overview

The AMR Action Fund is a large-scale investment initiative backed by major pharmaceutical companies to support the late-stage development of new antibiotics and bring them to market.

Portfolio and Signals

Invests in companies advancing:

Novel antibiotics targeting priority pathogens

Late-stage clinical candidates

Signal: Entry into this portfolio indicates:

Strong clinical promise

Commercial viability under current or evolving reimbursement models

Access and Engagement

No open application portal

Access typically via:

Existing investor networks

Strategic introductions

Prior validation (e.g., CARB-X, VC backing)

Notable AMR Examples / Programs

Late-stage antibiotic developers backed by major pharma coalition

Stay Updated

Stay connected so that you don't miss the latest AMR insights and updates.

Name(Required)